EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Prognostic value of combined digital PCR and multiparametric flow cytometry monitoring MRD in non-transplant acute myeloid leukemia

Shaojie Ye, Huimei Guo, Jianmei Xu, Xi Su, Lin Wang, Jiangbo Zhang, Jia Liu, Songying Zhao, Jing Wang, Hua Xue

Journal of Hematopathology · 14.04.2026 · 19 (1)

DOI: 10.1007/s12308-026-00692-8 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Hematopathology, online erschienen am 14.04.2026. Verfasst von Shaojie Ye und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, Hebei, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Flow Cytometry, Neoplasm, Residual, Polymerase Chain Reaction. Die Arbeit nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the synergistic prognostic value of digital PCR (dPCR)-based multigene measurable residual disease (MRD) monitoring combined with multiparametric flow cytometry (MFC) in patients with non-transplant acute myeloid leukemia (AML). METHODS: This observational cohort study analyzed 86 newly diagnosed AML patients (excluding APL) at the Affiliated Hospital of Hebei University (January 2018-May 2025). MRD was assessed using MFC (threshold: 0.1%) and dPCR (variant allele frequency [VAF] < 0.001%). Outcomes included relapse-free survival (RFS), overall survival (OS), and cumulative relapse rates. RESULTS: With a median follow-up time of 18.5 months, dPCR-MRD negativity predicted superior 2-year RFS (67.1% vs 42.3%, HR = 0.365, P = 0.003). Combined MFC/dPCR negativity further enhanced prognostic discrimination (2-year RFS: 68.2% vs 40.5%, HR = 0.323, P = 0.001). Subgroup analysis revealed MFC-driven RFS benefits in intensive chemotherapy (72.2% vs 33.3%, HR = 0.180, P = 0.014), while dual-platform monitoring showed trends favoring non-intensive regimens (58.7% vs 31.7%, HR = 0.407, P = 0.051). CONCLUSION: dPCR-MRD monitoring complements MFC for the stratification of risk of relapse, particularly among non-transplant AML patients. Dual-platform integration improves predictive accuracy, supporting personalized MRD-guided strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteFlow CytometryNeoplasm, ResidualPolymerase Chain ReactionHumansPrognosisFemaleMaleMiddle AgedAdultAgedYoung AdultAdolescent

Stichwörter der Autor:innen

Acute myeloid leukemiaDigital PCRMeasurable residual diseaseMultiparametric flow cytometryRelapse

Autor:innen und Institutionen

  • Department of Hematology, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, Hebei, China.
  • Department of Hematology, Affiliated Hospital of Hebei University, 212 Yuhua East Road, Baoding, 071000, Hebei, China. xh-xuehua@163.com.

Zitieren

APA

Ye, S., Guo, H., Xu, J., Su, X., Wang, L., Zhang, J., Liu, J., Zhao, S., Wang, J., & Xue, H. (2026). Prognostic value of combined digital PCR and multiparametric flow cytometry monitoring MRD in non-transplant acute myeloid leukemia. Journal of Hematopathology, 19(1). https://doi.org/10.1007/s12308-026-00692-8

Vancouver

Ye S, Guo H, Xu J, Su X, Wang L, Zhang J, et al. Prognostic value of combined digital PCR and multiparametric flow cytometry monitoring MRD in non-transplant acute myeloid leukemia. Journal of Hematopathology. 2026;19(1). doi:10.1007/s12308-026-00692-8

BibTeX
@article{Ye2026,
  author = {Ye, Shaojie and Guo, Huimei and Xu, Jianmei and Su, Xi and Wang, Lin and Zhang, Jiangbo and Liu, Jia and Zhao, Songying and Wang, Jing and Xue, Hua},
  title = {Prognostic value of combined digital PCR and multiparametric flow cytometry monitoring MRD in non-transplant acute myeloid leukemia},
  journal = {Journal of Hematopathology},
  year = {2026},
  volume = {19},
  number = {1},
  doi = {10.1007/s12308-026-00692-8}
}
Kostenlos starten →